FindTrial
Sign In

Clinical study of Esmolol protecting intestinal mucosal barrier function in patients with sepsis

Clinical study of Esmolol protecting intestinal mucosal barrier function in patients with sepsis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200066809
Enrollment
Unknown
Registered
2022-12-19
Start date
2023-01-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

Esmolol group:esmolol was pumped intravenously
control group:Conventional treatment

Sponsors

Nanjing Jiangbei Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: ? Age > 18 years old;? it met the diagnostic criteria of sepsis3.0 for sepsis;(3) mean arterial pressure > 65mmHg;(4) Norepinephrine dosage < 2µg? kg-1 ?min-1. The diagnostic criteria for sepsis were infection + Sequential organ failure score (SOFA)=2.

Exclusion criteria

Exclusion criteria: ? Pregnancy or perinatal period;(2) Acute myocardial infarction;(3) acute heart failure;(4) Heart rate < 60 beats/min;(5) Long-term use of ß-blockers before admission;(6) Severe asthma, chronic obstructive pulmonary disease, grade ? or above atrioventricular block.

Design outcomes

Primary

MeasureTime frame
heart rate;blood pressure;diamine oxidase;D - lactic acid;Intestinal fatty acid binding protein;catecholamine;Interleukin 6;—

Countries

China

Contacts

Public ContactLiu Shangxiang

Nanjing Jiangbei Hospital

liu18.00@163.com13914468265

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026